RxDoctor Payments Data

Paul Ruzumna, MD

Cardiovascular Disease · Arlington Heights, ILNPI 1033133111

Payments from drug & device makers

$2,004in general payments, 2019–2025

Across 88 payments — averaging $22.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$431
  • Novartis$364
  • Johnson & Johnson$289
  • Boston Scientific$223
  • Edwards Lifesciences$206
  • Pfizer$150
  • plus $341 from 8 others

What the payments were for

  • Food & beverage$2,004100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,004 in reported general payments places this provider in the 50th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$276,406
Medicare patients
2,296
Services billed
4,481

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban532$737,488
XareltoRivaroxaban164$207,272
Repatha SureclickEvolocumab58$64,707
EntrestoSacubitril/Valsartan46$60,235
MultaqDronedarone Hcl11$23,385
FarxigaDapagliflozin Propanediol28$20,821
WegovySemaglutide11$14,695
Rosuvastatin Calcium534$8,720
Ezetimibe290$7,951
Metoprolol Succinate453$7,371
Atorvastatin Calcium676$6,371
Irbesartan291$5,110
Carvedilol405$4,494
Diltiazem 24hr Er (Cd)Diltiazem Hcl152$4,021
Labetalol Hcl106$3,053

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$150$737,488532 claims
Johnson & JohnsonXarelto$289$207,272164 claims
NovartisEntresto$364$60,23546 claims
AstraZenecaFarxiga$57$20,82128 claims
Novo NordiskWegovy$82$14,69511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Arlington Heights

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →